Treatment days | No treatment days | P value* | ||||
---|---|---|---|---|---|---|
FF | MPAzeFlu | MF | OAH mono | |||
N users Day 1 | 331 (5.5%) | 159 (2.7%) | 351 (5.9%) | 1414 (23.6%) | 3736 (62.4%) | |
Symptoms Day 1 | ||||||
Runny nose (%) | 69 | 74 | 75 | 78 | 69 | 0.77 |
Itchy nose (%) | 68 | 55 | 65 | 67 | 57 | 0.006 |
Sneezing (%) | 79 | 73 | 76 | 87 | 77 | 0.20 |
Nasal congestion (%) | 75 | 74 | 79 | 71 | 64 | 0.37 |
Red eyes (%) | 50 | 44 | 42 | 52 | 42 | 0.56 |
Itchy eyes (%) | 70 | 64 | 68 | 74 | 64 | 0.22 |
Watery eyes (%) | 48 | 42 | 45 | 54 | 43 | 0.29 |
Impact of symptoms Day 1 | ||||||
Sleep (%) | 44 | 44 | 47 | 41 | 32 | 0.70 |
Daily activities (%) | 41 | 50 | 50 | 49 | 41 | 0.36 |
Work/school (%) | 31 | 42 | 33 | 33 | 27 | 0.02 |
Bothersome (%) | 76 | 77 | 77 | 78 | 74 | 0.94 |
ARIA score (%) | ||||||
0 | 11 | 11 | 12 | 11 | 16 | |
1 | 29 | 26 | 23 | 28 | 32 | |
2 | 30 | 24 | 27 | 26 | 24 | 0.08 |
3 | 19 | 16 | 23 | 21 | 16 | |
4 | 12 | 23 | 16 | 15 | 12 | |
Median [p25-75] | 2 [1–3] | 2 [1–3] | 2 [1–3] | 2 [1–3] | 2 [1–3] | 0.36 |
VAS global Day 1 (%) | ||||||
N | 331 | 159 | 351 | 1414 | 3736 | |
<20 | 17 | 18 | 16 | 16 | 30 | 0.53 |
20-49 | 32 | 28 | 33 | 26 | 28 | |
≥50 | 51 | 55 | 51 | 58 | 42 | |
Median [p25-75] | 50 [28–71] | 52 [25–73] | 50 [28–68] | 55 [30–75] | 40 [15–66] | 0.72 |
VAS global – all days (%) | ||||||
N days | 3186 | 2594 | 4093 | 9780 | 23,377 | |
N users | 507 | 256 | 548 | 2196 | 4569 | |
Average number of days per user± | 6.3 | 10.1 | 7.5 | 4.5 | 5.1 | |
<20 | 42 | 55 | 52 | 48 | 58 | 0.0001 |
20-49 | 32 | 27 | 30 | 28 | 24 | |
≥50 | 26 | 18 | 18 | 24 | 18 | |
Median [p25-75] | 26 [8–50] | 16 [6–38] | 19 [7–39] | 21 [7–48] | 14 [3–38] | 0.0001 |